An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
News|Videos|September 29, 2026
Oncology Pulsepoint: How ASCO’s New Breast Cancer Surveillance Guideline Changes Follow-Up
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer.
Advertisement
Advertisement
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, manager of clinical pharmacy services at Allegheny Health Network in Pittsburgh, discusses ASCO’s updated guideline for follow-up and surveillance after primary treatment for early-stage breast cancer. The update introduces a risk-based approach that groups patients by the intensity of surveillance they need, moving away from the same follow-up schedule for every patient.
Related to this article
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
Advertisement
Advertisement